Glaucoma

BOSTON – Vivid Vision software is indicated for treating convergence insufficiency, stereo depth perception, amblyopia and strabismus either in the clinic or at home, according to a presentation here at the American Academy of Optometry meeting.

BOSTON — The new FMAT1 measures tonometry, ophthalmodynamometry, tonography and ocular pulse amplitude, helping clinicians better manage glaucoma, J. James Thimons, OD, said at the American Academy of Optometry annual meeting.

NEW ORLEANS — In this Healio Video Perspective from the AAO meeting, Brian Flowers, MD, discusses results of the Glaukos iStent infinite trial in patients with advanced glaucoma.

BOSTON – The re:Vive from Heru is a wearable, modifiable, gameable, portable visual field system that can be used in a brightly lit room, Mitch Ibach, OD, said here at the American Academy of Optometry meeting.

BOSTON – The iStent inject and iStent inject W are trabecular meshwork bypass technologies performed to reduce patients’ risk of glaucoma progression and decrease medication burden, Mitch Ibach, OD, said here at the American Academy of Optometry meeting.

NEW ORLEANS — After 5 years of follow-up, eyes that received the Hydrus microstent for mild to moderate glaucoma required fewer medications and surgeries compared with eyes that underwent cataract surgery alone, according to a study.

NEW ORLEANS — It is important to trust clinical correlations when interpreting OCT scans to diagnose glaucoma, according to a speaker here at Glaucoma Subspecialty Day at the American Academy of Ophthalmology meeting.

NEW ORLEANS — In this Healio Video Perspective from the AAO meeting, Nathan Radcliffe, MD, discusses his experience using a new probe and approach to micropulse transscleral laser therapy for the treatment of glaucoma.

NEW ORLEANS — In this Healio Video Perspective from the AAO meeting, Dylan Stevens, MD, discusses artificial intelligence image detection recognition abilities as applied to fundus photos for the purpose of estimating cup-to-disc ratios.

NEW ORLEANS — In this Healio Video Perspective from the AAO meeting, John P. Berdahl, MD, discusses 2-year data from the iDose (sustained-release travoprost implant, Glaukos) phase 2 trial.